I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
Suramin Sodium has been observed as a potent inhibitor of melanoma HPA (heparanase) and tumor cell metastasis. Inhibition of NAD+-dependent deacetylase SIRT1 with an IC50 of 2.6 ?M along with SIRT5 has also been observed. Suramin Sodium has been recorded to antagonize EDG-3 (S1P3) selectively. Suramin Sodium is an inhibitor of A cyclase, FGF-1, FGF-2, IL-1, IL-4, PDGF, PC-PLD, PKC, SH-PTP, TERT, TGF beta 1, Topo I, Topo II and VEGF. It is used as a G protein uncoupler and inhibitor of PDGF, EGF, TGF-β, SIRT1 and SIRT5. It also blocks calmodulin binding to recognition sites and G protein coupling to G protein-coupled receptors. Increases open probability of ryanodine receptor (RyR) channels. Anticancer and antiviral agent.
Voogd et al. Recent research on the biological activity of suramin. Pharmacol.Rev. < span>1993, 45, (2), 177-203.
Beindl et al. Inhibition of receptor/G protein coupling by suramin analogues. Mol.Pharmacol. < span>1996, 50, (2), 415-23.